GCG and diabetes mellitus: Additionally, in trials for another novel glucose-lowering agent, glucagon-like peptide-1 (GLP-1) receptor agonists, the reported cardiovascular and kidney benefits are evident across a range of baseline diabetes variables, including those with longstanding disease and higher baseline HbA1c.